CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) Files An 8-K Other Events
Item 8.01
CATALYST PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 d863246dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Pre-Announces Estimated Firdapse® Revenues and Provides Updates on Advancement of Clinical Development Programs – Firdapse 2019 Net Product Revenues Expected to be Approximately $102 Million – Anticipates Full Year 2020 Firdapse Net Product Revenues to be in the Range of $135 million to $155 million – MuSK-MG Clinical Trial Has Met Enrollment Goals and is on Schedule to Report Top-Line Results in First Half of 2020 – Company is Accelerating Business Development Activities CORAL GABLES,…
To view the full exhibit click here
About CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company’s Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company’s CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette’s Disorder. The Company’s CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette’s Disorder, and epilepsy.
